Previous 10 | Next 10 |
Guerbet and Bracco Imaging Announce a Global Strategic Collaboration Agreement for Gadopiclenol Canada NewsWire Companies will collaborate on manufacturing and research and development for future indications, and will commercialize Gadopiclenol independently under sepa...
The following slide deck was published by Global Blood Therapeutics, Inc. in conjunction with this event. For further details see: Global Blood Therapeutics (GBT) presents at ASH Annual Meeting - Slideshow
GBT601 demonstrated average hemoglobin occupancy of greater than 30% with 100 mg daily doses in a multiple ascending dose study of six adult SCD patients GBT601 tolerability was favorable in studies of SCD patients and healthy volunteers Study results provide proof of conc...
Real-world experience study of more than 3,100 patients demonstrates statistically significant reductions in transfusions, vaso-occlusive crises and hospitalizations in patients treated with Oxbryta Phase 1 study of inclacumab also presented at ASH supports best-in-class potenti...
The following slide deck was published by Global Blood Therapeutics, Inc. in conjunction with this event. For further details see: Global Blood Therapeutics (GBT) GBT 2021 R&D Day
Although the Healthcare sector is having a positive year in absolute terms, that isn't the case in relative terms. Biotech stocks are having a difficult year, in spite of many of those trading at dirt-cheap valuations that don't even reflect the cash they have in-hand. It's very l...
GBT Supports the ASH Research Collaborative's Data Hub Sickle Cell Disease Program Grant of $400,000 to help expand sickle cell disease real-world data gathering in the U.S. PR Newswire WASHINGTON and SOUTH SAN FRANCISCO, Calif. , Dec. 2, 2021 /PRNewswire...
Amid the challenging COVID environment, Oxbryta is still generating double-digit sales growth. With the upcoming PDUFA set for December 25, Oxbryta is most likely to gain the label expansion to treat kids (ages 4-11), who are afflicted by sickle cell disease. Next year, Oxbryta is...
SOUTH SAN FRANCISCO, Calif., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in a virtual fireside chat at the 4th Annual Evercore ISI HealthCONx Conference on Wednesday, December 1, 2021, at 11:45 a.m. ET. ...
Image source: The Motley Fool. Global Blood Therapeutics (NASDAQ: GBT) Q3 2021 Earnings Call Nov 04, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Global Blood Therapeutics (GBT) Q3 2021 Earnings Call Transcript ...
News, Short Squeeze, Breakout and More Instantly...
Global Blood Therapeutics Inc. Company Name:
GBT Stock Symbol:
NASDAQ Market:
Global Blood Therapeutics Inc. Website:
Guerbet to Spotlight the Novel New Drug Elucirem™ (gadopiclenol) injection at the 2022 Radiological Society of North America Scientific Assembly and Annual Meeting PR Newswire Join us at Booth #1711 Opportunity to learn about the recently US FDA-approved nov...
The healthcare industry is growing at an unprecedented rate, and healthcare stocks are poised to benefit from this growth. This is large because healthcare companies are developing innovative new treatments and technologies that are transforming the way we care for our health. As a resu...
NEW YORK, NY / ACCESSWIRE / September 22, 2022 / New York, New York-Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: EVO Payments...